




## Product Introduction

### Nutlin-3a

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the **p53/MDM2** interaction with **IC50** of 90 nM.

#### Technical Data:

<b>Molecular Weight (MW):</b>	581.49	
<b>Formula:</b>	C30H30Cl2N4O4	
<b>Solubility (25°C)</b>	DMSO 100 mg/mL	
<b>* &lt;1 mg/ml means slightly soluble or insoluble:</b>	Water <1 mg/mL	
	Ethanol 100 mg/mL	
<b>Purity:</b>	>98%	
<b>Storage:</b>	3 years -20°C Powder 6 months -80°C in DMSO	
<b>CAS No.:</b>	675576-98-4	

#### Biological Activity

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10  $\mu$ M nutlin-3a led to >90% inhibition of NIH3T3 cells' growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJS-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg)

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJS-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

## References

- [1] Tovar C, et al. Proc Natl Acad Sci U S A, 2006, 103(6), 1888-1893.
- [2] Ohnstad HO, et al. BMC Cancer, 2011, 11(211), 1-11.
- [3] Vassilev LT, et al. Science, 2004, 303(5659), 844-848.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.